A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new combination shot as ...

the prevention of LRTD caused by RSV in people 18 through 59 years of age who are at increased risk for LRTD caused by RSV pregnant individuals at 32 through 36 weeks gestational age for the ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

A vote on April 16 will cover recommendations for three vaccines, including for respiratory syncytial virus and chikungunya, ...

After decades of fits and starts, scientists finally got the world’s first vaccines against respiratory syncytial virus ...

The U.S. Centers for Disease Control and Prevention's vaccine experts are expected to vote on expanding access to respiratory ...

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

The Advisory Committee on Immunisation Practices (ACIP) has voted to widen the recommendations on the use of RSV shots to ...

today announced that data from the Company’s Phase 2a human challenge study of EDP-323 in healthy adults infected with ...

Pfizer (PFE) announced that the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand ...

The CDC's Advisory Committee on Immunization Practices is meeting to review vaccine guidelines, including COVID-19 and ...